tiprankstipranks
Nektar Therapeutics (NKTR)
NASDAQ:NKTR

Nektar Therapeutics (NKTR) Stock Forecast & Price Target

1,154 Followers
See the Price Targets and Ratings of:

NKTR Analyst Ratings

Hold
1Ratings
0 Buy
1 Hold
0 Sell
Based on 1 analysts giving stock ratings to
Nektar
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

NKTR Stock 12 Months Forecast

Average Price Target

Based on 1 Wall Street analysts offering 12 month price targets for Nektar Therapeutics in the last 3 months. The average price target is with a high forecast of and a low forecast of . The average price target represents a change from the last price of $0.66.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"plus_tr_sans","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","-1":"-$1","0.25":"$0.25","1.5":"$1.5","2.75":"$2.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":null,"label":{"className":"overflowvisible_force","align":"right","x":60,"y":-17.5,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":"overflowvisible_force","align":"right","x":60,"y":-7.5,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":"overflowvisible_force","align":"right","x":60,"y":2.5,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">―</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.25,1.5,2.75,4],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2023","6":"Aug<br/>2023","9":"Nov<br/>2023","12":"Feb<br/>2024","25":"Feb<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.56,0.5169230769230769,0.4738461538461539,0.4307692307692308,0.3876923076923077,0.34461538461538466,0.30153846153846153,0.25846153846153846,0.2153846153846154,0.17230769230769233,0.12923076923076926,0.08615384615384614,0.04307692307692301,{"y":null,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.56,0.5169230769230769,0.4738461538461539,0.4307692307692308,0.3876923076923077,0.34461538461538466,0.30153846153846153,0.25846153846153846,0.2153846153846154,0.17230769230769233,0.12923076923076926,0.08615384615384614,0.04307692307692301,{"y":null,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.56,0.5169230769230769,0.4738461538461539,0.4307692307692308,0.3876923076923077,0.34461538461538466,0.30153846153846153,0.25846153846153846,0.2153846153846154,0.17230769230769233,0.12923076923076926,0.08615384615384614,0.04307692307692301,{"y":null,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.07,"date":1676592000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.57,"date":1677801600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.79,"date":1680825600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.82,"date":1683244800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.62,"date":1685664000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.55,"date":1688688000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.53,"date":1691107200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.6,"date":1693526400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.54,"date":1696550400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.55,"date":1698969600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.52,"date":1701388800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.54,"date":1704412800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.56,"date":1706832000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price TargetAverage Price TargetLowest Price Target
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
J.P. Morgan
Sell
Initiated
11/20/23
Nektar reinstated with an Underweight at JPMorganNektar reinstated with an Underweight at JPMorgan
TD Cowen
Buy
Upgraded
11/09/23
Positive Report for Nektar Therapeutics (NKTR) from TD Cowen
Mizuho Securities
$5.00
Hold
656.43%
Upside
Assigned
11/08/23
Nektar price target lowered to $5 from $6 at MizuhoNektar price target lowered to $5 from $6 at Mizuho
Leerink Partners
$1.50
Hold
126.93%
Upside
Reiterated
09/15/23
We are incrementally more positive on rezpeg’s (rezpegaldesleukin, Treg-biased PEGylated IL-2) prospects in atopic dermatitis (AtD) following Nektar’s (NKTR, MP) presentation of updated Ph 1b data and development plans. We are encouraged that rezpeg demonstrated consistent clinical benefit and dose response across multiple efficacy endpoints, including EASI, but also other outcomes including pruritus (itch) numeric rating scale (NRS) where Nektar teased out rezpeg benefit by excluding patients with low baseline scores (<4) from the analysis (Figure 1). We continue to be most excited that rezpeg seems to have disease-modifying potential with sustained benefit after cessation of dosing (Figure 2).
Bank of America Securities
$0.60
Sell
-9.23%
Downside
Reiterated
09/13/23
Nektar Therapeutics (NKTR) Gets a Sell from Bank of America Securities
Jefferies
$1.00
Hold
51.29%
Upside
Upgraded
05/09/23
Jefferies upgrades Nektar Therapeutics (NKTR) to a Hold
Goldman Sachs
$2.00
Sell
202.57%
Upside
Reiterated
04/17/23
Goldman Sachs Remains a Sell on Nektar Therapeutics (NKTR)
Stifel Nicolaus
$3.00
Hold
353.86%
Upside
Reiterated
03/02/23
Nektar Therapeutics (NKTR) PT Lowered to $3 at StifelStifel analyst Benjamin Burnett lowered the price target on Nektar Therapeutics (NASDAQ: NKTR) to $3.00 (from $4.70) while maintaining a Hold rating.

Best Analysts Covering Nektar Therapeutics

Which Analyst Should I Follow If I Want to Buy NKTR and Sell After:
1 Month
Jessica FyeJ.P. Morgan
Success Rate
8/15 ratings generated profit
53%
Average Return
+0.01%
initiated a sell rating 3 months ago
Copying Jessica Fye's trades and holding each position for 1 Month would result in 53.33% of your transactions generating a profit, with an average return of +0.01% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
3 Months
Jessica FyeJ.P. Morgan
Success Rate
7/15 ratings generated profit
47%
Average Return
+5.05%
initiated a sell rating 3 months ago
Copying Jessica Fye's trades and holding each position for 3 Months would result in 46.67% of your transactions generating a profit, with an average return of +5.05% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
1 Year
Jessica FyeJ.P. Morgan
Success Rate
10/15 ratings generated profit
67%
Average Return
+59.22%
initiated a sell rating 3 months ago
Copying Jessica Fye's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +59.22% per trade.
2 Years
Jessica FyeJ.P. Morgan
Success Rate
10/15 ratings generated profit
67%
Average Return
+62.49%
initiated a sell rating 3 months ago
Copying Jessica Fye's trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +62.49% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NKTR Analyst Recommendation Trends

Rating
May 23
Aug 23
Sep 23
Nov 23
Dec 23
Strong Buy
0
0
0
0
0
Buy
0
0
0
1
1
Hold
8
8
5
4
4
Sell
1
1
1
2
2
Strong Sell
0
0
0
0
0
total
9
9
6
7
7
In the current month, NKTR has received 1 Buy Ratings, 4 Hold Ratings, and 2 Sell Ratings. NKTR average Analyst price target in the past 3 months is .
Each month's total comprises the sum of three months' worth of ratings.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

NKTR Financial Forecast

NKTR Earnings Forecast

Next quarter’s earnings estimate for NKTR is -$0.21 with a range of -$0.33 to -$0.15. The previous quarter’s EPS was -$0.24. NKTR beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.58% of the time in the same period. In the last calendar year NKTR has Underperformed its overall industry.
Next quarter’s earnings estimate for NKTR is -$0.21 with a range of -$0.33 to -$0.15. The previous quarter’s EPS was -$0.24. NKTR beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.58% of the time in the same period. In the last calendar year NKTR has Underperformed its overall industry.

NKTR Sales Forecast

Next quarter’s sales forecast for NKTR is $21.43M with a range of $19.60M to $23.17M. The previous quarter’s sales results were $24.14M. NKTR beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 47.19% of the time in the same period. In the last calendar year NKTR has Outperformed its overall industry.
Next quarter’s sales forecast for NKTR is $21.43M with a range of $19.60M to $23.17M. The previous quarter’s sales results were $24.14M. NKTR beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 47.19% of the time in the same period. In the last calendar year NKTR has Outperformed its overall industry.

NKTR Stock Forecast FAQ

What is NKTR’s average 12-month price target, according to analysts?
Currently, no data Available
What is NKTR’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for NKTR, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
    How can I follow the stock ratings of top Wall Street analysts?
    Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
      Is NKTR a Buy, Sell or Hold?
      Nektar Therapeutics has a conensus rating of Hold which is based on 0 buy ratings, 1 hold ratings and 0 sell ratings.
        What is Nektar Therapeutics’s price target?
        Currently, no data Available
        What do analysts say about Nektar Therapeutics?
        Nektar Therapeutics’s analyst rating consensus is a Hold. This is based on the ratings of 1 Wall Streets Analysts.
          How can I buy shares of NKTR?
          Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
            What's Included in PREMIUM?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis